Abstract:Background: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis has been discovered for more than a decade, but the establishment of standardized immunotherapy protocol for pediatric patients still needs more clinical evidence. Methods: A multicenter, retrospective study was conducted on pediatric patients diagnosed with anti-NMDAR encephalitis between November 2011 and December 2018. The clinical records including clinical manifestations, immunotherapy strategies, and outcomes were collected and analyzed. Results: A total of 386 patients were included in our study and the median onset age was 8.00 (IQR 4.83-10.90) years. All patients received first-line immunotherapy and the majority (341, 88.3%) used the standard combination of methylprednisolone pulses (MEP) and intravenous immunoglobulins (IVIG), but 211 patients did not show satisfactory improvement (mRS ≥ 3). Mainly three treatment strategies were applied after first-line immunotherapy: second-line immunotherapy, repetitive first-line immunotherapy, and maintaining oral prednisolone. For patients with mRS ≥ 4 after first-line immunotherapy, the incidence of poor outcome (mRS ≥ 3) in oral prednisolone group was higher than that in other treatment groups (p = 0.039). No difference in complete recovery rate (mRS = 0) was found between patients receiving second-line and repetitive first-line immunotherapy, or patients using long-term and short-term prednisolone. Out of 149 patients who received anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab) test, 27 (18.12%) were positive. Patients with concomitantly positive MOG-Ab showed milder conditions compared to patients with typical anti-NMDAR encephalitis and were more inclined to relapses. We also identified female, MOG-Ab positive, and not receiving second-line and/or repetitive first-line immunotherapy were risk factors for relapses. Conclusions: For patients with mRS ≥ 4 after first-line immunotherapy and patients with concomitantly positive MOG-Ab, second-line immunotherapy is recommended. When second-line immunotherapy is not applicable, repetitive first-line immunotherapy can be considered as an option. Both second-line and repetitive first-line immunotherapy are beneficial to reduce relapse rate. The duration of sequential oral prednisolone can be shortened after fully evaluating patients' conditions.

Ofatumumab treatment for severe refractory anti-NMDAR encephalitis: A case series

Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody, in the Treatment of Severe Refractory Anti-N-methyl-D-Aspartate Receptor Encephalitis: Two Case Reports

Early Second‐line Therapy is Associated with Improved Episodic Memory in Anti‐nmda Receptor Encephalitis

Cognitive Function Recovery Pattern in Adult Patients with Severe Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Longitudinal Study

Successful treatment of relapsed and refractory CIDP with ofatumumab: a first case report

Case Report: Ofatumumab treatment in a patient with rituximab-intolerant refractory autoimmune GFAP astrocytopathy

A refractory anti-NMDA receptor encephalitis successfully treated by bilateral ovariectomy and intrathecal injection of methotrexate and dexamethasone: A case report

A meaningful exploration of ofatumumab in refractory NMOSD: a case report

The case report of MOG and NMDAR IgG double positive encephalitis treated with subcutaneous ofatumumab

First-line Immunotherapy of Neuronal Surface Antibody-Mediated Autoimmune Encephalitis: Assessment of Therapeutic Effectiveness and Cost-Efficiency

Efficacy and Safety of Rituximab in Chinese Children With Refractory Anti-NMDAR Encephalitis

Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis

Case report: Rapid recovery after intrathecal rituximab administration in refractory anti-NMDA receptor encephalitis: report of two cases

Protein A immunoadsorption for the treatment of refractory anti-N-methyl-d-aspartate receptor encephalitis: A single-center prospective study

Immunotherapy in Probable autoimmune encephalitis without detected autoantibody

Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis

Immunotherapies for Anti-N-M-methyl-D-aspartate Receptor Encephalitis: Multicenter Retrospective Pediatric Cohort Study in China.

Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis

Anti-SRP immune-mediated necrotizing myopathy responsive to ofatumumab: a case report

Efficacy and Safety of Rituximab Treatment for Anti-N-Methyl-d-Aspartate Receptor Encephalitis Without Tumor in Children

Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series